Tracking HIV drug resistance in Eastern Europe and Russia
Observes how HIV drug resistance spreads in adults as new anti-HIV drugs arrive.
Plain-language title generated from the registry record
Registry title: HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
Key facts
- Where
- Siena, ItalySee the site
Where in Italy
- University Hospital of SienaSiena, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Euresist Network GEIE
- Trial code
- NCT06127290
- Record updated
- 27 February 2025
- Original description
Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.Read full original descriptionShow less
HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.
Inclusion: naïve patients starting 2nd generation INSTI treatment; first line patients under 2nd generation INSTI treatment with either viral RNA sequence before therapy start, or PBMC available with PBMC sample date not more than 3 years from therapy start date (with reasonably sure history of no failure in the interval from therapy start date to PBMC sample date]).
Exclusion: patients not having Signed Informed consent for the present study, if required by local authorities iii) Persons aged < 18 at baseline; patients not having a signed informed consent for the EIDB data repository, if required by local/national legislation in order to have data in the common data repository.